Skip to main
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio is currently facing some challenges with the expiry of their patents for their NAV Technology Platform, leading to potential increases in competitive pressures. However, the company's current focus and priority on higher-priority programs such as RGX-202 and ABBV-RGX-314, both of which are expecting pivotal data this year, could potentially offset any negative impacts. Despite the delay in the potential launch of RGX-121 to 2027 and the decrease in its probability of launch to 60% due to regulatory uncertainties, we reiterate our Buy rating as the company's overall outlook and portfolio is positive, with a price target of $50.

Bears say

Regenxbio is facing several potential challenges, which could affect the company's value and likelihood of success in the long term. These include regulatory setbacks, competition in an increasingly crowded gene therapy market, potential safety issues, and the need for additional capital to continue developing its pipeline. Additionally, the company's focus on rare diseases may present challenges in recruiting patients for clinical trials and obtaining regulatory approval. These risks should be carefully considered by investors before making any decisions regarding the company's stock.

REGENXBIO (RGNX) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 10 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.